BridgeBio Pharma, Inc.
BBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2,285.3% | -88% | 11.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98.3% | 73.7% | 95.6% | 95.5% |
| R&D Expenses | $1 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -267.2% | -6,528.8% | -659.6% | -827.1% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$0 | -$1 |
| % Margin | -241.4% | -6,913.9% | -619.7% | -806.9% |
| EPS | -2.88 | -3.95 | -3.35 | -4.43 |
| % Growth | 27.1% | -17.9% | 24.4% | – |
| EPS Diluted | -2.88 | -3.95 | -3.35 | -4.43 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$0 | -$1 |
| % Margin | -196.9% | -6,078.3% | -511.9% | -765.7% |